Epivir Hbv

Epivir Hbv

Dosage

100mg

Package

180 pill 120 pill 90 pill 60 pill 30 pill

Total price: 0.0

In our pharmacy, you can purchase Epivir Hbv without a prescription, with worldwide delivery within 7–21 days. Discreet and secure packaging guaranteed.
Epivir Hbv treats chronic hepatitis B by inhibiting hepatitis B virus (HBV) replication through action as a nucleoside reverse transcriptase inhibitor, blocking viral DNA synthesis.
The standard adult dosage is 100 mg taken once daily, with adjustments for renal impairment based on physician guidance.
Available as 100 mg tablets or 5 mg/mL oral solution for convenient administration.
Rapid absorption achieves peak plasma concentration within 1–1.5 hours after dosing.
Maintains antiviral effects for approximately 24 hours, supporting once-daily dosing regimens.
Strict avoidance of alcohol is essential due to heightened risk of liver damage in hepatitis B patients.
The most frequent side effects include headache, fatigue, nausea/vomiting, diarrhea, cough, sore throat, and elevated liver enzymes.
Ready to start your Epivir Hbv treatment without prescription requirements?

Trackable delivery 5-9 days

Payment method Visa, MasterCard, Discovery, Bitcoin, Ethereum

Free delivery (by Standard Airmail) on orders over A$306

Basic Epivir Hbv Information

Detail	Information
INN (International Nonproprietary Name)	Lamivudine
Brand names (Australia)	Epivir HBV, Zeffix, generic lamivudine products
ATC Code	J05AF05
Forms & dosages	100mg tablets; 5mg/mL oral solution
Australian manufacturers	GlaxoSmithKline (originator); TGA-approved generics
TGA registration status	Approved for chronic hepatitis B treatment
Classification	Prescription only (S4)

Epivir HBV belongs to the nucleoside reverse transcriptase inhibitor class of antivirals. The Therapeutic Goods Administration in Australia regulates this hepatitis B medication, requiring strict prescription protocols. Common packaging includes 60-tablet bottles and 240mL oral solution bottles. Tablets should always be stored below 25°C with careful protection from moisture.

How Epivir Hbv Halts The Hepatitis B Virus

Epivir HBV interrupts the hepatitis B virus lifecycle by mimicking naturally occurring cytosine nucleosides. After entering infected liver cells, it integrates into growing HBV DNA chains during viral replication. This integration acts like a faulty building block, causing premature termination of DNA synthesis which prevents the virus from multiplying successfully.

Peak concentration timing: Reaches maximum blood levels within 1-2 hours after administration
Steady state achievement: Consistent therapeutic levels established within 2-4 days of regular dosing
Metabolic pathway: Minimal liver processing; activated inside cells through phosphorylation
Elimination profile: Primarily cleared by kidneys as unchanged drug with an elimination half-life of 5-7 hours

Significant medication interactions must be considered for safe therapy. Trimethoprim-sulfamethoxazole combinations can increase lamivudine levels and require monitoring. Complete avoidance of alcohol is advised due to combined hepatotoxicity risks. Concurrent use with interferon alfa demands caution given potential pancreatitis development, requiring symptom awareness including severe abdominal pain with vomiting.

Approved Uses & Special Cases In Australia

In Australia, Epivir HBV carries TGA approval for chronic hepatitis B infection management in adults (age 16+). Suitable candidates demonstrate compensated liver disease alongside observable viral replication markers and liver inflammation evidence. The treatment aims to achieve virological suppression and potentially hepatitis B e-antigen seroconversion through extended therapy.

Off-Label Use	Australian Protocol
Children (2-16 years)	Weight-adjusted dosing only under specialist hepatologist supervision
Pregnancy (Category B3)	Consider when benefits outweigh risks; mandatory infant monitoring for potential mitochondrial dysfunction

Absolute contraindications include confirmed hypersensitivity reactions to lamivudine or any tablet component. Crucially, this HBV formulation should never be administered if untreated HIV co-infection exists. Using the lower hepatitis B dosage without complete antiretroviral therapy risks generating HIV resistance due to subtherapeutic exposure.

Special caution remains necessary with renal impairment patients, who require tailored dosage adjustments initiated only after creatinine clearance assessment. Medical teams must remain vigilant for post-treatment acute hepatitis flare-ups, necessitating planned withdrawal protocols and close viral monitoring.

Epivir Hbv dosage guide for Australian patients

Patient Group	Daily Dose	Treatment Duration
Adults & adolescents (16+)	100 mg tablet	Minimum 1 year or longer based on viral response
Renal impairment (CrCl 30-49 mL/min)	100 mg initial dose, then 50 mg daily	Requires continuous renal function monitoring
Renal impairment (CrCl <30 mL/min)	25 mg initial dose, then 25 mg every 48 hours	Not recommended without specialist supervision

Missed dose instructions: Take Epivir Hbv immediately upon remembering unless nearing next scheduled dose. Never double dose. Oral solution requires careful handling - store below 25°C, discard 30 days after opening. Keep containers tightly closed and protect from direct sunlight.

Epivir Hbv safety profile and precautions

TGA boxed warnings: Sudden discontinuation risks severe hepatitis flare-ups requiring hospitalisation. Undiagnosed HIV co-infection may develop resistance at low HBV doses. Regular clinical monitoring essential throughout treatment.

Lactic acidosis presents urgent medical risk - symptoms include unusual muscle pain, breathing difficulties and stomach discomfort with nausea. Pancreatitis cases remain rare but require immediate care when abdominal pain radiates to the back. Epivir Hbv packaging contains galactose derivatives unsuitable for patients with rare metabolic disorders.

Liver function tests establish baselines before therapy begins, particularly for cirrhotic patients. Quarterly blood counts monitor potential side effect developments. Some individuals report numbness or tingling sensations in extremities since nerve tissues occasionally react to treatment. Pregnancy considerations involve specialist consultation due to limited safety data.

Medication interactions require attention - trimethoprim/sulfamethoxazole combinations increase lamivudine exposure. Pharmacists recommend spacing Epivir Hbv two hours apart from magnesium/aluminum antacids which reduce absorption effectiveness. Routine viral testing tracks HBV DNA levels and HBeAg seroconversion progress throughout therapy.

Epivir HBV: Understanding Its Role in Hepatitis B Treatment

**International Nonproprietary Name (INN):** **Lamivudine** **Brand Names & Packaging:** Lamivudine targeting hepatitis B is marketed as **Epivir-HBV** in many countries. Common brand names and packagings for hepatitis B include: - **Epivir-HBV** (USA, UK, Canada): tablets 100 mg (bottles/boxes of 60), oral solution 5 mg/mL (bottles of 240 mL)[1][3]. - In the EU (e.g., Germany, Romania), it is sold as "Lamivudin" with similar tablet strength and packaging. Local packaging may list the active ingredient as "Lamivudină" (Romanian spelling). - Other global brand names include **Heptodin**, **Zeffix™**, and various generics depending on region and supplier. **ATC Code (and Classification):** - **J05AF05** - J: Anti-infectives for systemic use - 05: Antivirals for systemic use - AF: Nucleoside and nucleotide reverse transcriptase inhibitors - 05: Lamivudine **Forms & Dosages Sold:** | Form | Dosage(s) | Packaging Description | |-----------------|-------------|---------------------------------------------| | Tablet | 100 mg | 60 tablets per bottle/box | | Oral solution | 5 mg per mL | 240 mL bottle | **Local Manufacturers & World-Based Suppliers:** - **GlaxoSmithKline plc** (GSK) is the primary holder for Epivir-HBV. - Multiple local generics may exist, especially in the EU and Asian markets. **Registration & Approval Status:** - **FDA (USA):** Approved for hepatitis B treatment as Epivir-HBV (NDA 021003)[3]. - **EU (EMA):** Approved under various names with standard hepatitis B indications. - **Romania/ANMDMR:** Registered as "Lamivudină", ANMDMR public databases confirm its approval for chronic hepatitis B. For up-to-date approvals, refer to ANMDMR’s national database. - **Other agencies:** Typically approved wherever chronic hepatitis B is prevalent. **Classification:** - **Prescription Only (Rx)**[1][2] **Indications:** - **Chronic hepatitis B** with evidence of viral replication and active liver inflammation[1]. **Standard Dosages:** | Patient Group | Typical Dosage | Notes | |-------------------|-----------------|----------------------------------------------------------| | Adults/adolescents| 100 mg once daily| With or without food[1][4] | | Children (per product labels)| Insufficient data for <16 for chronic HBV[3] | Used off-label, weight-based dosing in some cases, but always under specialist supervision. | **Dosage Adjustments:** - **Children:** Safety and efficacy for chronic HBV not well established under age 16[3]. - **Elderly:** Standard starting doses; monitor renal function. - **Renal impairment:** Dose adjustment required; consult specific renal dosing tables. - **Hepatic impairment:** No adjustment generally needed[3]. **Typical Treatment Durations & Regimens:** - Chronic therapy: Usually long-term, reassessed regularly; minimum 6-12 months, often continued until virological endpoints are met (HBV DNA suppression, hepatitis B e antigen seroconversion)[1][4]. - Discontinuation should only occur per physician advice due to risk of severe hepatitis exacerbation. **Instructions for Missed Doses/Overdose:** - **Missed dose:** Take as soon as remembered unless it is almost time for next dose – do not double up. - **Overdose:** Seek immediate medical attention; main effects are exacerbations of adverse reactions[2][3]. **Storage and Transport Guidelines:** - Store at room temperature, 20–25°C (68–77°F). - Oral solution: Protect from light; do not freeze[3]. **Absolute Contraindications:** - Known hypersensitivity to lamivudine or any excipient of the formulation[3]. **Relative Contraindications / Cautions:** - **HIV infection:** Epivir-HBV uses a lower lamivudine dose than for HIV; monotherapy or suboptimal dosing can lead to HIV resistance[2][3]. - **Renal impairment:** Dose adjustment and close monitoring required. - Hepatitis B reactivation possible after discontinuation. **Common Side Effects (Mild to Moderate):** - **Headache** - **Fatigue** - **Respiratory symptoms:** cough, sore throat - **GI symptoms:** diarrhea, nausea, vomiting, abdominal pain - **Elevated liver enzymes**[1][4] **Market Competitors & Related Products:** | Substance | Brand Names/INN | Indication | Notes | |---------------|----------------------|-------------------------|-----------------------------| | **Entecavir** | Baraclude, generics | Chronic hepatitis B | More potent; also first-line| | **Tenofovir** | Viread, Tenofovir | Chronic hepatitis B | High barrier to resistance | | **Adefovir** | Hepsera | Chronic hepatitis B | Less used due to nephrotox. | **SEO-Optimized Use-Cases & Additional Information:** - Epivir-HBV is widely available for **chronic hepatitis B treatment** in adults. - It is not recommended for **HIV mono- or co-infection** at HBV dosages due to risk of resistance[3]. - Generic lamivudine for HBV is often available at lower cost in many countries. - Epivir-HBV maintains its global status as a **core antiviral for HBV**, especially when cost or availability of other agents is limited. **Summary:** Epivir-HBV (lamivudine) is a prescription antiviral approved worldwide for chronic hepatitis B, available as 100 mg tablets and 5 mg/mL oral solution, requiring strict adherence and regular monitoring for maximum efficacy and resistance prevention. It is a first-line or alternative antiviral option, especially where access to other agents is limited or contraindicated.

Comparing Hepatitis B Antiviral Options

Treatment	Price for 28-day supply (±2%)	Key Advantages	Clinical Considerations
Epivir HBV	$38.50	Budget-friendly; PBS-listed	Higher resistance risk than newer options
Baraclude (Entecavir)	$52.80	Higher barrier to resistance	Preferred for treatment-naïve patients
Viread (Tenofovir)	$42.20	Effective against resistant HBV strains	Requires kidney function monitoring

Clinical trends: Australian prescribers increasingly choose entecavir for initial therapy but use Epivir HBV where medication costs are prohibitive.

Essential Patient Guidance

Administration Essentials

Timing: Establish fixed daily dosing (e.g., breakfast) regardless of meals
Avoid: Combining with St John’s Wort; separate antacids by 2+ hours
Storage: Protect tablets from humidity; discard discoloured solutions

Safety Considerations

Never discontinue abruptly: Stopping treatment without medical oversight frequently causes dangerous hepatitis flares. Ongoing viral load monitoring is essential - detectable HBV DNA after 6 months may indicate required therapy change.

Medication Access Tips

PBS Authority codes apply - confirm eligibility with prescribing doctor. Batch numbers vary annually; always verify TGA registration on packaging.